PubMed Health⌕ Search

Biomedical subjects

R Baliga

Publications and source records attributed to R Baliga.

38 records · Page 3Linked to original sources

Focal segmental glomerulosclerosis in children with acute lymphocytic leukemia: case reports and review of literature.

PURPOSE: To report the occurrence of focal segmental glomerulosclerosis (FSGS) in children with acute lymphocytic leukemia (ALL), discuss pathogenesis and problems in management. PATIENTS AND METHODS: Progressive renal dysfunction developed in two adolescent black girls with high-risk ALL who underwent renal biopsies that were consistent with FSGS. In both patients, no known etiologic factors, such as systemic lupus erythematosus, poststreptococcal glomerulonephritis, sickle cell anemia, or acquired immunodeficiency syndrome, were evident. FSGS induced by Adriamycin (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats. The patients had received anthracyclines and methotrexate, a known nephrotoxic chemotherapeutic agent. RESULTS: One patient progressed to chronic renal failure and required prolonged dialysis followed by renal transplantation, though the leukemia remained in remission. The other patient is also in remission and on maintenance treatment for leukemia. She has persistent proteinuria and is currently undergoing a trial of high-dose steroid therapy. CONCLUSION: The combination of FSGS with leukemia poses a management challenge to the clinician in terms of further treatment with potentially nephrotoxic drugs, complications of nephrotic syndrome (including infections), and timing of renal transplantation. Future studies should address whether FSGS represents a glomerular response to anthracycline-induced injury in susceptible black persons.

Adolescent↗

Effect of iron chelator, hydroxyl radical scavenger and cytochrome P450 inhibitors on the cytotoxicity of cisplatin to tumor cells.

BACKGROUND: Iron catalyzed reactive oxygen metabolites (ROM) are important mediators in cisplatin (CP)-induced nephrotoxicity, and cytochrome P450 (CYP) is the major source of this iron. Iron chelators, hydroxyl radical scavengers and CYP inhibitors have shown marked protection. MATERIAL AND METHODS: This study was designed to determine whether these agents affect the tumoricidal efficacy of CP to LLC-WRC 256 tumor cells. RESULTS: CP was cytotoxic to the tumor cells in a dose and time dependent manner. Iron chelator, hydroxyl radical scavenger and CYP inhibitors did not reduce the cytotoxic effect of CP. Exposure of the tumor cells to CP did not increase the catalytic iron release and the generation of hydroxyl radical. Both CYP activity and content in the tumor cells were less than 10% of that in the rat liver. CONCLUSION: We speculate that iron chelator, hydroxyl radical scavenger and CYP inhibitors do not alter the antitumor efficacy of CP.

Animals↗